Evidence mapPaperPMID 41299038Full record

ArticleCommunications medicine2025

A multimodal framework for comprehensive driver variant prediction in cancer.

Hai Yang, Yijia Chen, Tianyi Zhou, Yingzhuo Wang, Qin Zhou, Ting Xiao, Qian Zhang, Jing Zhang, Dongdong Li, Zhe Wang

Abstract read
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hai Yang *Key Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.ORCID http://orcid.org/0000-0002-1161-4337
Yijia Chen *Department of Computer Science and Engineering, East China University of Science and Technology, Shanghai, China.
Tianyi ZhouThe Electrical Engineering and Computer Science department, The University of Michigan, Ann Arbor, USA.
Yingzhuo WangFaculty of Engineering, Imperial College London, London, UK.
Qin ZhouKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.
Ting XiaoKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.
Qian ZhangKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.
Jing ZhangKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.
Dongdong LiKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China.
Zhe WangKey Laboratory of Smart Manufacturing in Energy Chemical Process Ministry of Education, East China University of Science and Technology, Shanghai, China. wangzhe@ecust.edu.cn.ORCID http://orcid.org/0000-0002-3759-2041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCancer genomes contain many mutations, but only a subset drive tumor development. Accurately pinpointing these driver variants remains challenging. We aim to build an accurate and interpretable model by combining DNA sequence, protein 3D structure, and cancer omics data.

methodsWe present ModVAR, a multimodal model that integrates DNA sequences, predicted protein tertiary structures, and cancer omics data to classify driver variants. The approach uses pre-trained models (DNAbert2 and ESMFold) and a self-supervised strategy for cancer omics profiles. We evaluate performance on clinically and experimentally validated driver variants with standard classification metrics, examine therapeutic relevance through molecular docking, assess modeling of variants in intrinsically disordered protein regions, and analyze modality contributions.

resultsHere we show that ModVAR achieves strong accuracy across benchmarks for identifying validated driver variants. It prioritizes variants with potential therapeutic actionability supported by docking analyses, and the inclusion of structural predictions enables effective modeling of variants in intrinsically disordered regions. Interpretation indicates that the protein structure modality contributes most to predictions. At scale, the method produces 3,971,946 publicly available variant annotations.

conclusionsModVAR integrates sequence, structure, and cancer omics signals to aid driver-variant discovery. It provides robust performance across tasks, supports hypothesis generation and target discovery, and supplies a large-scale resource that advances cancer research and personalized therapy.

Identifiers

PMID41299038
PMCPMC12657954

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.